Company news

BioCryst Pharmaceuticals, Inc. news in 2024

BioCryst Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.

View company

BioCryst Launches ORLADEYO® (berotralstat) in Ireland

November 17, 2024

BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update

November 3, 2024

BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat)

October 23, 2024

BioCryst to Report Third Quarter 2024 Financial Results on November 4

October 20, 2024

BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)

October 13, 2024

BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting

October 9, 2024

BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome

October 1, 2024

U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile

September 29, 2024

BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium

September 5, 2024

BioCryst Appoints Dr. Donald Fong Chief Medical Officer

September 4, 2024

BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update

August 4, 2024

BioCryst to Report Second Quarter 2024 Financial Results on August 5

July 21, 2024

ORLADEYO® (berotralstat) Approved in Peru

July 8, 2024

BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment

June 1, 2024

BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology

May 13, 2024

ORLADEYO® (berotralstat) Approved in Mexico

May 12, 2024

BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)

May 8, 2024

BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update

May 5, 2024

BioCryst to Report First Quarter 2024 Financial Results on May 6

April 21, 2024

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency

April 16, 2024

BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones

February 25, 2024

BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment

February 22, 2024

BioCryst Launches ORLADEYO® (berotralstat) in Italy

February 18, 2024

BioCryst to Report Fourth Quarter 2023 Financial Results on February 26

February 11, 2024

BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

February 4, 2024

BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability

January 4, 2024

BioCryst to Present at 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Calls in 2024

Decks in 2024